Paper Details

  1. Home
  2. Paper Details

Olanzapine versus haloperidol treatment in first-episode psychosis.

Author: BeasleyC, GrundyS, LiebermanJ A, SangerT M, TohenM, TollefsonG D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examined the efficacy and safety of olanzapine and haloperidol treatment in patients with first-episode psychosis, emphasizing the importance of early intervention for preventing morbidity and mortality associated with schizophrenia.
Paper Details　
Original Abstract of the Article :
It has been hypothesized that the morbidity and mortality associated with schizophrenia can be prevented by providing effective treatment during the first episode of psychosis. Hence, the authors examined patients with first-episode psychosis to determine the efficacy and safety of olanzapine and ha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/ajp.156.1.79

データ提供：米国国立医学図書館（NLM）

Olanzapine vs. Haloperidol: Choosing the Right Path for First-Episode Psychosis

First-episode psychosis, like a sudden desert storm, can be a frightening and disorienting experience. This research examines the efficacy and safety of two antipsychotic medications, olanzapine and haloperidol, in treating first-episode psychosis. The authors analyzed data from patients experiencing their first episode of psychosis, comparing the effects of olanzapine and haloperidol treatment. Their findings provide valuable insights into the potential benefits and risks of each medication in this specific context.

Navigating the Complexities of Psychosis Treatment

The research highlights the importance of considering the individual needs of patients with first-episode psychosis. The authors emphasize that the choice between olanzapine and haloperidol should be made on a case-by-case basis, taking into account factors such as patient characteristics, symptom profile, and potential side effects. This personalized approach can help optimize treatment outcomes and improve patient well-being.

Finding the Right Treatment Path

If you or someone you know is experiencing psychosis, it's crucial to seek professional help from a mental health professional or psychiatrist. They can provide a thorough evaluation, determine the most appropriate course of treatment, and offer support throughout the journey of managing psychosis. Early intervention and personalized care are essential for achieving the best possible outcomes.

Dr.Camel's Conclusion

Just as a camel chooses the safest path through a desert landscape, healthcare professionals must carefully consider the various treatment options for first-episode psychosis. This research provides valuable insights into the comparative effectiveness of olanzapine and haloperidol, helping guide clinicians towards the most appropriate treatment choices for individuals experiencing this challenging condition.

Date :
  1. Date Completed 1999-01-27
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

9892301

DOI: Digital Object Identifier

10.1176/ajp.156.1.79

Related Literature

Article Analysis
・Effective treatment of schizophrenia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.